EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene-replacement therapy in neurodevelopmental disorders: progress and challenges

Holger Lerche, Ulrike Bs Hedrich, Thomas V Wuttke

Journal of Clinical Investigation · 03.02.2025 · 135 (3)

DOI: 10.1172/jci188703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.02.2025. Verfasst von Holger Lerche und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, and. Hauptthemen laut MEDLINE: Genetic Therapy, Neurodevelopmental Disorders, GABA Plasma Membrane Transport Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterozygous loss-of-function variants in the SLC6A1 gene, encoding GAT1, which is the main GABA transporter in the brain, lead to a broad spectrum of neuropsychiatric and neurodevelopmental disorders including epilepsy, developmental delay, intellectual disability, and autism. Gene-replacement strategies involving adeno-associated viruses (AAV) require the delivery of genes to specific types of neurons or areas in the brain, likely during certain developmental time points. In this issue of the JCI, Guo and colleagues from the Gray lab evaluated two promoters, three injection modalities, and various timing strategies for replacement of GAT1 via AAV type 9 in heterozygous and homozygous knockout mouse models. Intrathecal administration of vectors containing either promoter at postnatal day 5 achieved high expression and was the best tolerated approach. Notably, gene-replacement therapy failed at later disease stages, suggesting the importance of early gene reconstitution and confirming the importance of GABA metabolism in early brain development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyNeurodevelopmental DisordersGABA Plasma Membrane Transport ProteinsAnimalsHumansMiceDependovirusMice, Knockout

Substanzen

GABA Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, and.
  • Department of Neurosurgery, University of Tübingen, Tübingen, Germany.

Zitieren

APA

Lerche, H., Hedrich, U. B., & Wuttke, T. V. (2025). Gene-replacement therapy in neurodevelopmental disorders: progress and challenges. Journal of Clinical Investigation, 135(3). https://doi.org/10.1172/jci188703

Vancouver

Lerche H, Hedrich UB, Wuttke TV. Gene-replacement therapy in neurodevelopmental disorders: progress and challenges. Journal of Clinical Investigation. 2025;135(3). doi:10.1172/jci188703

BibTeX
@article{Lerche2025,
  author = {Lerche, Holger and Hedrich, Ulrike Bs and Wuttke, Thomas V},
  title = {Gene-replacement therapy in neurodevelopmental disorders: progress and challenges},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {3},
  doi = {10.1172/jci188703}
}
Kostenlos starten →